Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 8/20 | 0.73 |
| ▸ | BRAF | P15056 | 8/20 | 0.69 |
| ▸ | EGFR | P00533 | 7/20 | 0.63 |
| ▸ | ABL1 | P00519 | 1/20 | 0.60 |
| ▸ | RET | P07949 | 2/20 | 0.59 |
| ▸ | CSF1R | P07333 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28054361 | 0.92 | KIT (0.62) | KITBRAFRET | |
| SCHEMBL27997206 | 0.89 | KIT (0.58) | KITBRAFEGFRABL1CSF1R | |
| SCHEMBL5900523 | 0.89 | KIT (0.69) | KITBRAFEGFRABL1RET | |
| SCHEMBL29562470 | 0.86 | BRAF (0.82) | KITBRAFEGFRABL1RET | |
| SCHEMBL6184307 | 0.86 | BRAF (0.82) | KITBRAFEGFRABL1RET | |
| SCHEMBL5900538 | 0.85 | KIT (0.65) | KITBRAFEGFRABL1RET | |
| SCHEMBL30904911 | 0.85 | KIT (0.71) | KITBRAFEGFRABL1 | |
| SCHEMBL20912769 | 0.85 | KIT (0.71) | KITBRAFEGFRABL1 | |
| SCHEMBL12871531 | 0.84 | KIT (0.84) | KITBRAFEGFRABL1 | |
| SCHEMBL4254621 | 0.84 | KIT (0.77) | KITBRAFEGFRABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11225474-B2 | Crystalline salt forms of 3-(1,2,4-triazolo[4,3-a]pyridine-3-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-trifluoromethylphenyl)benzamide for medical application | LIMITED LIABILITY COMPANY «FUSION PHARMA» | 2022-01-18 | — | — | US | disclosed |
| US-20200325131-A1 | NOVEL CRYSTALLINE SALT FORMS OF 3-(1,2,4-TRIAZOLO[4,3-A]PYRIDINE-3-YLETHYNYL)-4-METHYL-N-(4-((4-METHYLPIPERAZIN-1-YL)METHYL)-3-TRIFLUOROMETHYLPHENYL)BENZAMIDE FOR MEDICAL APPLICATION | LIMITED LIABILITY COMPANY <<FUSION PHARMA>> (RU) | 2020-10-15 | — | — | US | disclosed |
| WO-2020007234-A1 | ALKYNYL(HETERO)AROMATIC COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | 深圳市塔吉瑞生物医药有限公司 | 2020-01-09 | — | — | WO | disclosed |
| CN-105837575-B | 3- acetenyl Pyrazolopyrimidine derivative and its preparation method and application | 四川大学 | 2019-01-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11225474-B2 | Crystalline salt forms of 3-(1,2,4-triazolo[4,3-a]pyridine-3-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-trifluoromethylphenyl)benzamide for medical application | ABL2, ALK, ABL1 | KIT 88/4885BRAF 113/4885EGFR 524/4885 |
| US-20200325131-A1 | NOVEL CRYSTALLINE SALT FORMS OF 3-(1,2,4-TRIAZOLO[4,3-A]PYRIDINE-3-YLETHYNYL)-4-METHYL-N-(4-((4-METHYLPIPERAZIN-1-YL)METHYL)-3-TRIFLUOROMETHYLPHENYL)BENZAMIDE FOR MEDICAL APPLICATION | ABL2, SRC, ABL1 | KIT 121/4885BRAF 98/4885EGFR 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.